Corline Biomedical AB

SSE:CLBIO.ST

13.8 (SEK) • At close February 20, 2024
Bedrijfsnaam Corline Biomedical AB
Symbool CLBIO.ST
Munteenheid SEK
Prijs 13.8
Beurswaarde 296,573,040
Dividendpercentage 0%
52-weken bereik 8.92 - 19.85
Industrie Biotechnology
Sector Healthcare
CEO Dr. Henrik Nittmar Ph.D.
Website https://www.corline.se

An error occurred while fetching data.

Over Corline Biomedical AB

Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications. Its products are based on Corline Heparin Conjugate (CHC) technology, a heparin conjugate that is used as stand-alone pharmaceutical compound. The company's products include Renaparin for use in the treatment

Vergelijkbare Aandelen

Ortivus AB (publ) logo

Ortivus AB (publ)

ORTI-B.ST

3.44 SEK

aXichem AB logo

aXichem AB

AXIC-A.ST

1.7 SEK

Active Biotech AB (publ) logo

Active Biotech AB (publ)

ACTI.ST

0.685 SEK

ProstaLund AB (publ) logo

ProstaLund AB (publ)

PLUN.ST

1.575 SEK

Clinical Laserthermia Systems AB (publ) logo

Clinical Laserthermia Systems AB (publ)

CLS-B.ST

0.102 SEK

Magle Chemoswed Holding AB (publ) logo

Magle Chemoswed Holding AB (publ)

MAGLE.ST

27.6 SEK

Financiële Gegevens

Cijfers zijn in miljoenen (SEK)

Cijfers zijn in miljoenen (SEK)